Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — total revenues of $60.11M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues increased by 83.8% year-over-year, from $32.7M to $60.11M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — total revenues has grown at a 100.2% compound annual growth rate (CAGR), from $23.64M to $189.76M.
- What does single reportable segment — total revenues mean?
- This metric captures the total gross inflows of economic benefits arising from the sale of pharmaceutical products and services during the reporting period. It serves as the primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Growth in this figure reflects the company's ability to scale its commercial operations and capture market share.